Quick Answer
Dogwood Therapeutics, Inc. reported Net Income Loss of -$34.26 million for the year ending 2025.
- Dogwood Therapeutics, Inc. showed a decrease of -177.4% in Net Income Loss from 2024 to 2025.
- This data is from Dogwood Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$466.6 thousand | Q2 2020: -$654.6 thousand | Q3 2020: -$2.72 million | Q1 2021: -$3.06 million | Q2 2021: -$4.28 million | Q3 2021: -$4.11 million | Q1 2022: -$3.96 million | Q2 2022: -$3.67 million | Q3 2022: -$2.58 million | Q1 2023: -$1.52 million | Q2 2023: -$1.44 million | Q3 2023: -$1.24 million | Q1 2024: -$1.29 million | Q2 2024: -$1.05 million | Q3 2024: -$2.28 million | Q1 2025: -$10.92 million | Q2 2025: -$3.81 million | Q3 2025: -$15.74 million.
- Over the full 6 years of available data (2020 to 2025), Dogwood Therapeutics, Inc.'s Net Income Loss has declined by 231.1%.
- Historical annual values: Fiscal year 2025: -$34.26 million | Fiscal year 2024: -$12.35 million | Fiscal year 2023: -$5.30 million | Fiscal year 2022: -$12.25 million | Fiscal year 2021: -$15.96 million | Fiscal year 2020: -$10.35 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: